AACR Cancer Progress Report 2023: Contents

CPR23 – A Snapshot of a Year in Progress

A Snapshot of a Year in Progress

Between August 1, 2022, and July 31, 2023, FDA approved 14 new anticancer therapeutics, 12 previously approved therapeutics for treating new cancer types, and two new diagnostic imaging agents.

CPR23 – Cancer in 2023

Cancer in 2023

In the United States, the overall cancer death rate has been steadily declining since the 1990s, translating into more than 3.8 million cancer deaths avoided. However, progress has not been uniform against all cancer types, and there are stark inequities in the cancer burden among many sociodemographic groups.

CPR23 – Understanding the Path to Cancer Development

Understanding the Path to Cancer Development

Cancer is a collection of diseases that are characterized by unchecked cell multiplication. Both acquired and inherited genetic mutations, as well as modifications inside and outside the cell, can contribute to cancer development.

CPR23 – Reducing the Risk of Cancer Development

Reducing the Risk of Cancer Development

In the U.S., 40 percent of all cancers are associated with modifiable risk factors. The decline in cancer mortality over the past 30 years is largely attributable to reductions in smoking and increased screening.

CPR23 – Screening for Early Detection

Screening for Early Detection

Extensive research has shown that routine cancer screening saves lives. Advances in medical research are underscoring the potential for artificial intelligence and minimally invasive screening tests as new frontiers in early detection of cancer.

CPR23 – Advancing the Frontiers of Cancer Science and Medicine

Advancing the Frontiers of Cancer Science and Medicine

Advances in novel and innovative approaches to surgery, radiotherapy, chemotherapy, molecularly targeted therapy, and immunotherapy—the five pillars of cancer treatment—are saving and improving lives.

CPR23 – Spotlight on Immunotherapy: Pushing the Frontier of Cancer Medicine

Spotlight on Immunotherapy: Pushing the Frontier of Cancer Medicine

Cancer immunotherapeutics work by unleashing the power of a patient’s immune system to fight cancer and have emerged as one of the most exciting new approaches to cancer treatment. As of July 31, 2023, at least 23 different cancer immunotherapeutics have been approved by the FDA.

CPR23 – Perspective: Looking to the Future of Immunology

Perspective: Looking to the Future of Immunology

In this special section, Nobel Laureate James P. Allison, PhD, FAACR, and Padmanee Sharma, MD, PhD, discuss how bringing clinical trials, immune profiling, discovery science, data science, and drug development together on a coordinated team can accelerate the path of new drugs and drug combinations to the clinic.

CPR23 – Supporting Cancer Patients and Survivors

Supporting Cancer Patients and Survivors

Cancer survivors face unique challenges, but lifestyle factors like diet and exercise as well as caregiving resources like patient navigators, clinical care coordinators, and patient advocates can enhance patient outcomes.

CPR23 – Envisioning the Future of Cancer Science and Medicine

Envisioning the Future of Cancer Science and Medicine

Innovative technologies such as artificial intelligence and wearable devices, and novel approaches such as modulating the human microbiome, will drive progress against a wide range of cancers, including those that have been especially difficult to treat.

CPR23 – Advancing the Future of Cancer Research and Patient Care Through the Adoption of Evidence-based Policies

Advancing the Future of Cancer Research and Patient Care Through the Adoption of Evidence-based Policies

Federally funded research can accelerate the pace of new scientific breakthroughs against cancer, while policies and public health programs can ensure that the benefits of those advances are shared equitably.

CPR23 – Conclusion

Conclusion

This 13th edition of the Cancer Progress Report documents the unprecedented progress against cancer and underscores how continued investments in cancer research will ensure that treating and curing all cancers is within our reach.

CPR23 – AACR Call to Action

AACR Call to Action

The extraordinary advances against cancer detailed in this report were made possible by investment in biomedical research. To continue this progress, the AACR calls on Congress to provide robust, sustained, and predictable annual funding increases for NIH, NCI, FDA, and CDC in FY 2024 and beyond.

CPR23 – A Message from AACR

A Message from AACR

We are in an era of extraordinary scientific progress against cancer fueled by research-driven breakthroughs across the spectrum of cancer science. To maintain the momentum against cancer, we must ensure that medical research remains a national priority for our policymakers.

CPR23 – Executive Summary

Executive Summary

Unprecedented progress in medical research is increasing our understanding of the collection of diseases we call cancer and is driving remarkable improvements in cancer prevention, early detection, diagnosis, and treatment.

CPR23 – Steering Committee

Steering Committee

2023-2024 AACR President Philip D. Greenberg, MD, FAACR, serves as the chair of the Steering Committee for the AACR Cancer Progress Report 2023.